Study S002351

Weight Loss and Treatment Patterns in a Real World Population of Adults Receiving Saxenda® for Weight Management in Routine Clinical Practice in Switzerland

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05153590
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 269
Start: 2021-12-03
Primary completion: 2022-04-15
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity or Overweight
Interventions: DRUG:Saxenda®
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1263-5715

Registered primary outcomes

Relative change in body weight greater than or equal to 5% (lower BMI with weight related comorbidities) or greater than or equal to 7% (higher BMI) in reimbursed setting (yes/no) [From Baseline (Week 0) to Week 16]
Relative change in body weight greater than or equal to 5%, conditionally to relative change greater than or equal to 5% or greater than or equal to 7% at Week 16 in reimbursed setting(yes/no) [From Week 16 to Month 10]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.